Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CENTURY THERAPEUTICS, INC.

(IPSC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Earnings Flash (IPSC) CENTURY THERAPEUTICS Reports Q3 Loss $-0.48

11/10/2021 | 07:36am EST


ę MT Newswires 2021
All news about CENTURY THERAPEUTICS, INC.
01/13CENTURY THERAPEUTICS, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
01/11CENTURY THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (..
AQ
01/10Century Therapeutics, Bristol Myers Squibb Sign Cancer Research Collaboration Agreement
MT
01/10Century Therapeutics Shares Rise 12% Premarket After Bristol Myers Deal
DJ
01/10CENTURY THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale..
AQ
01/04Century Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021CENTURY THERAPEUTICS, INC.(NASDAQGS : IPSC) added to S&P Global BMI Index
CI
2021CENTURY THERAPEUTICS, INC.(NASDAQGS : IPSC) added to NASDAQ Biotechnology Index
CI
2021Century Therapeutics to Join Nasdaq Biotechnology Index
MT
2021Century Therapeutics Added to the NASDAQ Biotechnology Index
GL
More news
Analyst Recommendations on CENTURY THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -93,3 M - -
Net cash 2021 343 M - -
P/E ratio 2021 -4,51x
Yield 2021 -
Capitalization 819 M 819 M -
EV / Sales 2021 -
EV / Sales 2022 40,6x
Nbr of Employees -
Free-Float -
Chart CENTURY THERAPEUTICS, INC.
Duration : Period :
Century Therapeutics, Inc. Technical Analysis Chart | IPSC | US15673T1007 | MarketScreener
Technical analysis trends CENTURY THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 14,49 $
Average target price 36,00 $
Spread / Average Target 148%
EPS Revisions
Managers and Directors
Osvaldo Flores Chief Executive Officer & Director
Douglas Carr Vice President-Finance & Operations
Joseph Jimenez Chairman
Hyam I. Levitsky President-Research & Development
Cynthia M. Butitta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CENTURY THERAPEUTICS, INC.-8.64%819
MODERNA, INC.-19.39%83 008
LONZA GROUP AG-15.15%52 584
IQVIA HOLDINGS INC.-12.33%47 252
SEAGEN INC.-11.33%25 068
ICON PUBLIC LIMITED COMPANY-13.98%21 684